RecruitingPhase 4NCT07246564

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

An Open-label, Prospective, Single-arm Study Assessing the Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Sponsor

UCB Biopharma SRL

Enrollment

40 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Myasthenia Gravis

Summary

The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Rozanolixizumab for people with myasthenia gravis. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRozanolixizumab

Subcutaneous infusion

Locations(12)

Mg0033 20040

Beijing, China

Mg0033 20261

Changchun, China

Mg0033 20295

Changsha, China

Mg0033 20348

Fuzhou, China

Mg0033 20269

Guangzhou, China

Mg0033 20185

Jinan, China

Mg0033 20347

Jinan, China

Mg0033 20172

Shanghai, China

Mg0033 20184

Shenzhen, China

Mg0033 20204

Suzhou, China

Mg0033 20180

Wuhan, China

Mg0033 20349

Xuzhou SHI, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07246564

Related Trials

Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis

NCT074119631 location

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

NCT0721758717 locations

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT0728442024 locations

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

NCT076737442 locations

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT0729417029 locations